LOGIN  |  REGISTER
Cue Biopharma
Chimerix

Clover Health to Present at Canaccord Genuity 43rd Annual Growth Conference and 2023 Wells Fargo Healthcare Conference

August 02, 2023 | Last Trade: US$3.21 0.12 -3.60

FRANKLIN, Tenn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to improving health equity for seniors, today announced its participation in the following investor conferences:

  • CEO, Andrew Toy, will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 8:00 a.m. Eastern Time.
  • CFO, Scott J. Leffler, will present at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6, 2023, at 10:15 a.m. Eastern Time.

A live webcast and reply of the presentations will be accessible from Clover Health's investor relations website at https://investors.cloverhealth.com/.

About Clover Health

Clover Health (Nasdaq: CLOV) is a physician enablement company committed to bringing access to great healthcare to everyone on Medicare. This includes a health equity-based focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. We operate two distinct lines of business: Insurance and Non-Insurance. Through our Insurance line of business, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. Our Non-Insurance line of business similarly aims to reduce cost-of-care while enhancing the quality of care for patients enrolled in Original Medicare.

Press Contact:
Andrew Still-Baxter
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations Contact:
Ryan Schmidt
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page